Arvinas announces new patient-reported outcomes data from VERITAC-2 trial

Arvinas (ARVN) announced new patient-reported outcomes data from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant, which are being presented in a mini oral session at the 2025 European Society for Medical Oncology Congress. Vepdegestrant is a novel investigational PROteolysis TArgeting Chimera estrogen receptor degrader which is being developed with Pfizer (PFE) as a potential monotherapy for estrogen receptor 1 mutated, estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer previously treated with endocrine-based therapy. In the VERITAC-2 clinical trial, patients with ESR1-mutated disease treated with vepdegestrant reported a statistically significant delay in deterioration of overall quality of life, pain, and multiple functioning domains compared to those who received fulvestrant. These findings complement previously reported clinical efficacy and safety data from the VERITAC-2 clinical trial, reinforcing vepdegestrant as a potential treatment option for patients with ESR1-mutated ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy. In patients with ESR1-mutated disease, vepdegestrant demonstrated a reduced risk of deterioration compared to fulvestrant which was statistically significant in several PRO domains including overall health status, pain severity, and functioning, and vepdegestrant consistently showed reduced risk of deterioration versus fulvestrant across all PRO domains. The company believes these data support vepdegestrant’s opportunity to be a potential best-in-class therapy for patients with ESR1-mutated ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine therapy. Also presented at ESMO 2025 were results from the TACTIVE-N Phase 2 clinical trial, which evaluated neoadjuvant vepdegestrant in postmenopausal women with ER+/HER2- localized breast cancer. The results presented showed that neoadjuvant vepdegestrant demonstrated biological and clinical activity in this treatment-naive, predominantly ESR1 wild-type population of postmenopausal women with ER+/HER2- localized breast cancer.